Dermatan sulfate as a bifunctional antithrombotic

Cardiovascular Drug Reviews

Volumn 17, Issue 3, 1999, Pages 225-236

  Onaya, Junichi ^a   Kyogashima, Mamoru ^a   Sakai, Tokiko ^a   Arai, Mikio ^a   Miyauchi, Satoshi ^a   Sakamoto, Takashi ^a   Takada, Akikazu ^b  

^a SEIKAGAKU CORPORATION   (Japan)

^b HAMAMATSU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Anticoagulation Fibrinolysis; Dermatan sulfate; Glycosaminoglycans; Heparin cofactor II Tissue plasminogen activator

Indexed keywords

DERMATAN SULFATE; GLYCOSAMINOGLYCAN; HEPARIN COFACTOR; TISSUE PLASMINOGEN ACTIVATOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTICOAGULATION; ANTIGENICITY; CONTROLLED STUDY; DRUG EFFECT; ENDOTHELIUM CELL; EXTRACELLULAR MATRIX; FIBRINOLYSIS; NONHUMAN; PLASMINOGEN ACTIVATION; PRIORITY JOURNAL; RAT; REVIEW; THROMBOGENESIS; THROMBOSIS; VENOUS STASIS;

EID: 0033381826     PISSN: 08975957     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1527-3466.1999.tb00016.x     Document Type: Review

References (26)

1. Abbadini M, Zhu GJ, Maggi A, Pangrazzi J, Donati MB, Mussoni L. Dermatan sulfate induces plasminogen activator release in the perfused rat hindquarters. Blood 1987;70:1858-1860.
2. Barrowcliffe TW, Johnson EA, Thomas DP. Low molecular weight heparin. New York: John Wiley & Sons, 1992.
3. Casu B, Oreste P, Torri G, et al. The structure of heparin oligosaccharide fragments with high-anti-(factor Xa) activity containing the minimal antithrombin III-binding sequence. Chemical and 13C nuclear-magnetic-resonarce studies. Biochem J 1981;197:599-609.
4. Dejana E, Villa S, de Gaetano G. Bleeding time in rats: A comparison of different experimental conditions. Thromb Haemost 1982;48:108-111.
5. Dol F, Caranobe C, Dupouy D, et al. Effects of increased sulfation of dermatan sulfate on its in vitro and in vivo pharmacological properties. Thromb Res 1988;52:153-164.
6. Gandley RE, McLaughlin MK, Koob TJ, Little SA, McGuffee LJ. Contribution of chondroitin-dermatan sulfate-containing proteoglycans to the function of rat mesenteric arteries. Am J Physiol 1997;273:H952-960.
7. Jackson RL, Bush SJ, Cardin AD. Glycosaminoglycans: Molecular proteins, protein interactions, and role in physiological process. Physiol Rev 1991:71:481-539.
8. Kjellen L, Lindahl U. Proteoglycans: Structures and interactions. Anna Rev Biochem 1991;60:443-475.
9. Kluft C, Brakman P. Effect of euglobulin fibrinolysis: Involvement of Cl inactivator. In: Davidson JF et al., eds. Progress in chemical fibrinolysis and thrombolysis. Vol. 1. New York: Raven, 1975.
10. Kresse H, Hausser H, Schonherr E. Small proteoglycans. Experientia 1993;49:403-416.
11. Krupinski K, Bielawiec M, Yoshida K. Kyogashima M, Takada Y, Takada A, Dermatan sulfate enhances the lysis of laser-induced thrombus in vivo. Thromb Res 1998;91:199-202.
12. Linhardt RJ, Al-Hakim A, Liu J, et al. Structural features of dermatan sulfate and their relationship to anticoagulant and antithrombotic activities. Biochem Pharmacol (Suppl 1) 1991;42:1609-1619.
13. Linhardt RJ, Desai UR, Liu J, Pervin A, Hoppensteadt D, Fareed J. Low molecular weight dermatan sulfate as an antithrombotic agent. Structure-activity relationship studies. Biochem Pharmacol 1994;47:1241-1252.
14. Maimone MM, Tollefsen DM. Structure of a dermatan sulfate hexasaccharide that binds to heparin cofactor II with high affinity. J Biol Chem 1990;265:18263-18271.
15. Muller-Berghaus G. Pathophysiologic and biochemical events in disseminated intravascular coagulation. Dysregulation of procoagulant and anticoagulant pathway. Semin Thromb Hemost 1989;15:58-86.
16. Nakamura M, Kimura S, Kobayashi M, Hirano K, Hoshino T, Awaya S. Type VI collagen bound to collagen fibrils by chondroitin/dermatan sulfate glycosaminoglycan in mouse corneal stroma. Jpn J Ophthalmol 1997;41:71-76.
17. Onaya J, Kyogashima M, Sunose A, Miyauchi S. Mizuno S, Horie K. Effects of dermatan sulfate, a heparin cofactor II mediated thrombin inhibitor, on the endotoxin-induced disseminated intravascular coagulation model in the rat: Comparison with low-molecular-weight heparin, nafamostat mesilate and argatroban. Jpn J Pharmacol 1998;76:397-404.
18. Reyers I, Mussoni L, Donati MB, de Gaetano G. Failure of aspirin at different doses to modify experimental thrombosis in rats. Thromb Res 1980;18:669-674.
19. Rijiken DC, Juhan-Vague I, DeCock F, Collen D. Measurement of human tissue-type plasminogen activator by a two-site immunoradiometric assay. J Lab Clin Med 1983;101:274-284.
20. Tollefsen DM, Pestka CA, Monafo WJ. Activation of heparin cofactor II by dermatan sulfate. J Bio Chem 1983;258:6713-6716.
21. Tollefsen DM, Peacock ME, Monafo WJ. Molecular size of dermatan sulfate oligosaccharides required to bind and activate heparin cofactor II. J Bio Chem 1986;261:8854-8858.
22. Urano T, Sakakibara K, Rydzewski R, Urano S, Takada Y, Takada A. Relationships between euglobulin clot lysis time and the plasma levels of tissue plasminogen activator and plasminogen activator inhibitor 1. Thromb Haemost 1990;63:82-86.
23. Takada Y, Urano T, Takada A. Effects of heparin sulfate analogue or other sulfated polysaccharides on the activation of plasminogen by t-PA or u-PA. Thromb Res 1994;73:301-311.
24. Thunberg L, Backstrom G, Lindahl U. Further characterization of the antithrombin-binding sequence in heparin. Carbohydr Res 1982;100:393-410.
25. Walker ID, Davidson JF. Assessment of fibrinolysis. In: Bloom AL et al., eds. Haemostasis and thrombosis. Vol. 1. 3rd ed. Edinburgh: Churchill Livingstone, 1994.
26. Yoshikawa T, Furukawa Y, Murakami M, Takemura S, Kondo M. Experimental model of disseminated intravascular coagulation induced by sustained infusion of endotoxin. Res Exp Med 1981;179:223-228.